Expanding the spectrum of monoclonal light chain deposition disease in muscle

被引:11
作者
Ostrow, Lyle W. [1 ]
Corse, Andrea M. [1 ]
Morrison, Brett M. [1 ]
Huff, Carol A. [2 ]
Carrino, John A. [3 ]
Hoke, Ahmet [1 ]
Mammen, Andrew L. [1 ]
机构
[1] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA
[2] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[3] Johns Hopkins Sch Med, Dept Radiol, Baltimore, MD 21205 USA
关键词
amyloid; gammopathy; light chain deposition; MRI; myopathy; PRIMARY SYSTEMIC AMYLOIDOSIS; AL-TYPE AMYLOIDOSIS; MULTIPLE-MYELOMA; MYOPATHY; SERUM; FEATURES; KAPPA; PATIENT; ASSAYS;
D O I
10.1002/mus.23287
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: The diagnosis of amyloid myopathy is delayed when monoclonal gammopathies are not detected on initial testing and muscle biopsies are nondiagnostic, and the EMG and symptoms can mimic an inflammatory myopathy. Methods: Case report of a patient presenting with severe progressive muscle weakness of unclear etiology despite an extensive workup including two nondiagnostic muscle biopsies. Results: Directed by MRI, a third biopsy revealed amyloid angiopathy and noncongophilic kappa light chain deposition in scattered subsarcolemmal rings and perimysial regions. A serum free light chain (FLC) assay revealed a kappa monoclonal gammopathy, which was not detected by multiple immunofixations. Conclusions: The spectrum of immunoglobulin deposition in muscle is similar to other organs. It comprises a continuum that includes parenchymal amyloid deposition, amyloid angiopathy, and noncongophilic Light Chain Deposition Disease (LCDD). We recommend including the FLC assay in the routine investigation for monoclonal gammopathies. This case also highlights the value of MRI-guided muscle biopsy. Muscle Nerve 45: 755-761, 2012
引用
收藏
页码:755 / 761
页数:7
相关论文
共 27 条
  • [11] Hull KM, 2001, ARTHRITIS RHEUM-US, V44, P1954, DOI 10.1002/1529-0131(200108)44:8<1954::AID-ART333>3.0.CO
  • [12] 2-S
  • [13] Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease
    Kaplan, Batia
    Ramirez-Alvarado, Marina
    Sikkink, Laura
    Golderman, Sicilia
    Dispenzieri, Angela
    Livneh, Avi
    Gallo, Gloria
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (05) : 705 - 715
  • [14] Isolated myopathy as the initial manifestation of primary systemic amyloidosis
    Karacostas, D
    Soumpourou, M
    Mavromatis, I
    Karkavelas, G
    Poulios, I
    Milonas, I
    [J]. JOURNAL OF NEUROLOGY, 2005, 252 (07) : 853 - 854
  • [15] AN AUTOPSY CASE OF LIGHT-CHAIN DEPOSITION DISEASE
    KASAHARA, N
    TAMURA, H
    MATSUMURA, O
    NAGASAWA, R
    SUZUKI, Y
    OHGIDA, T
    ITOYAMA, S
    MITARAI, T
    ISODA, K
    [J]. INTERNAL MEDICINE, 1994, 33 (04) : 216 - 221
  • [16] KATZ B, 1989, J CLIN NEURO-OPHTHAL, V9, P39
  • [17] Diagnostic performance of quantitative κ and λ free light chain assays in clinical practice
    Katzmann, JA
    Abraham, RS
    Dispenzieri, A
    Lust, JA
    Kyle, RA
    [J]. CLINICAL CHEMISTRY, 2005, 51 (05) : 878 - 881
  • [18] Mandl LA, 2000, J RHEUMATOL, V27, P949
  • [19] METZLER JP, 1992, SKELETAL RADIOL, V21, P463
  • [20] CASE OF THE MONTH - AMYLOIDOSIS CAUSING A PROGRESSIVE MYOPATHY
    NADKARNI, N
    FREIMER, M
    MENDELL, JR
    [J]. MUSCLE & NERVE, 1995, 18 (09) : 1016 - 1018